Find Reports
Select Report Type
Reimbursement Review
Displaying 1176 - 1200 of 1426
Please scroll or swipe to the right to view the full content.
| Title | Brand Name | Generic Name | Files | Therapeutic Area | Recommendation Type | Status | Submission Date | Recommendation Date Sort ascending | Project Number |
|---|---|---|---|---|---|---|---|---|---|
| Liraglutide | Victoza | Liraglutide | Diabetes Mellitus, Type 2 | Withdrawn | SR0505-000 | ||||
| trofinetide | Daybue | trofinetide | Rett syndrome (RTT) | Active | SR0829-000 | ||||
| pasireotide | Signifor LAR | pasireotide | Acromegaly, adults | Active | SR0859-000 | ||||
| daratumumab | Darzalex SC | daratumumab | Multiple myeloma, eligible for autologous stem cell transplant | Active | PC0388-000 | ||||
| crovalimab | TBC | crovalimab | paroxysmal nocturnal hemoglobinuria (PNH) | Active | SR0858-000 | ||||
| Pharmaceutical Reviews Update ... | |||||||||
| semaglutide | Wegovy | semaglutide | Weight management | Active | SR0841-000 | ||||
| durvalumab, olaparib, carbopla... | Imfinzi, Lynparza | durvalumab, olaparib, carboplatin, paclitaxel | Endometrial cancer that is mismatch repair proficient (pMMR) | Withdrawn | PC0366-001 | ||||
| durvalumab, carboplatin, pacli... | Imfinzi | durvalumab, carboplatin, paclitaxel | Endometrial cancer that is mismatch repair deficient (dMMR) | Active | PC0366-000 | ||||
| ruxolitinib | Opzelura | ruxolitinib | Nonsegmental vitiligo | Active | SR0835-000 | ||||
| guselkumab | Tremfya | guselkumab | Ulcerative colitis | Active | SR0874-000 | ||||
| blinatumomab | Blincyto | blinatumomab | B-cell precursor acute lymphoblastic leukemia | Active | PC0365-000 | ||||
| Ibrance for Advanced Breast Ca... | Ibrance | Palbociclib | Withdrawn | PC0068-000 | |||||
| Mifepristone and misoprostol | Mifegymiso | Mifepristone and misoprostol | Medical termination of pregnancy (gestational age up to 49 days) | Withdrawn | SR0473 -000 | ||||
| ibrutinib | Imbruvica | ibrutinib | Leukemia | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | NS0004-000 | |||
| durvalumab | Imfinzi | durvalumab | resectable non-small cell lung cancer (NSCLC) | Active | PC0372-000 | ||||
| Pharmaceutical Reviews Update ... | |||||||||
| garadacimab | TBC | garadacimab | Hereditary angioedema (HAE) | Active | SR0860-000 | ||||
| donanemab | TBC | donanemab | Alzheimer's disease | Suspended | SR0857-000 | ||||
| Voriconazole | VFEND | Voriconazole | Aspergillosis, Invasive | Withdrawn | SR0020-000 | ||||
| Mixed amphetamine salts | Adderall XR | Mixed amphetamine salts | Attention deficit hyperactivity disorder | Withdrawn | SR0027-000 | ||||
| Omalizumab | Xolair | Omalizumab | Asthma, severe persistent | Cancelled | SR0035-000 | ||||
| Escitalopram oxalate | Cipralex | Escitalopram oxalate | Depression, Major Depressive Disorder (MDD) | Withdrawn | SR0039-000 | ||||
| Mirabegron | Myrbetriq | Mirabegron | Overactive bladder | Withdrawn | SR0319-000 | ||||
| Canagliflozin | Invokana | Canagliflozin | Diabetes Mellitus, Type 2 | Withdrawn | SR0335-000 |
Health Technology Review
Displaying 601 - 602 of 602
Horizon Scan
Displaying 101 - 110 of 110
Projects in Progress
Displaying 26 - 27 of 27
View All Reports
Displaying 1176 - 1200 of 2138
Please scroll or swipe to the right to view the full content.
Provisional Funding Algorithm
Displaying 76 - 81 of 81